Reliant Technologies Receives FDA Clearance for Fraxel Re:Fine™ Laser System
Fraxel re:fine system enables clinicians to expand their practice and access the $400 million aesthetic market with safe, gentle, non-invasive skin rejuvenation
SAN DIEGO—MAY 7, 2007—Reliant Technologies, Inc., the pioneer of fractional resurfacing and market leader of aesthetic laser skin treatments, today announced that it has received FDA clearance for the Fraxel re:fine laser system. The clearance is a significant milestone in this new approach to noninvasive skin rejuvenation and the latest addition to the Fraxel®family of products. The Fraxel re:fine laser system has been designed to offer patients an additional choice in skin rejuvenation treatments that would provide a gentle, yet effective, treatment for pigmentation, texture, tone and periorbital fine lines with limited pain and downtime. The Fraxel re:fine laser system will be launched at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting, May 7-9.
"The approval of Fraxel re:fine treatment reinforces Reliant's commitment to developing and marketing innovative treatments for patients of every skin type," said Eric Stang, president and chief executive officer of Reliant Technologies. "The Fraxel re:fine system is the best option for clinicians who want a mild yet effective treatment option for their patients interested in tone, texture and pigmentation refinement, along with the safety, ease of use and predictable results found in all Fraxel products."
Zakia Rahman, M.D., clinical instructor of dermatology at Stanford University in Palo Alto, Calif., and medical director of the Fraxel Laser Clinic is leading ongoing research studies of the Fraxel re:fine laser system. Dr. Rahman has performed more than 100 procedures to date proving that the Fraxel re:fine treatment improves patients' pigmentation, texture, tone and periorbital fine lines with limited downtime and discomfort. The research also shows that the Fraxel re:fine system rejuvenates skin by combining a more superficially absorbed laser wavelength with the unique Fraxel fractional delivery method.
Thanks in part to non-invasive laser treatments, the aesthetics market last year generated more than $400 million in revenue with clinicians performing approximately 9 million aesthetic laser procedures. By incorporating the Fraxel re:fine system to their practices, clinicians have immediate access to this valuable patient base.
"For physicians such as OB/GYNs, family physicians and those who are simply looking to expand their practice into a growing sector, the Fraxel re:fine system is the ideal treatment to boost their bottom line," said Anja Krammer, vice president of marketing. "With the Fraxel re:fine system, clinicians now have the perfect auxiliary service to bring extra revenue to their practice while offering expanded treatment options to their patients who show an evolving desire to look as young as they feel."
About the Fraxel Systems
The Fraxel® family of products, which includes the Fraxel re:store™ laser system (formerly called the Fraxel SR 1500 laser), the Fraxel re:pair™ laser system and the Fraxel re:fine™laser system, has quickly become the industry standard for aesthetic skin treatment. Unlike traditional laser devices, Fraxel-brand systems treat only a fraction of skin at a time, leaving the surrounding area intact for fast healing. Fraxel lasers have received multiple FDA clearances and have been found safe and effective in treating all skin types and all areas of the face and body.
The Fraxel re:fine laser, offering superficial nonablative skin rejuvenation, combines the unique method of fractional delivery with a lighter treatment. Performed in 20-25 minutes, Fraxel re:fine treatment is excellent for OBGYNs and family physicians seeking a safe and gentle option.
The prototype Fraxel re:pair* laser has been proven in clinical studies to improve severe photodamage, including rhytids, skin laxity and vascular lesions. The product, employing Fractional Deep Dermal Ablation (FDDATM treatment), was introduced to plastic and dermatologic surgeons at the American Society for Lasers in Medicine & Surgery annual scientific meeting in April 2007.
The Fraxel re:store laser, delivering Nonablative Fractional Resurfacing (NFRTM treatment), was introduced in 2004 and has been quickly adopted by more than 1,000 dermatologists, plastic surgeons and aesthetic physicians worldwide. It is the accepted gold standard for treating acne scars and periorbital wrinkles, and for skin resurfacing procedures on the face, neck, chest and hands.
About Reliant Technologies
Reliant Technologies develops clinical solutions to repair and rejuvenate aging and environmentally damaged skin. Reliant is dedicated to providing the most advanced research, engineering and products to the global aesthetic marketplace. The company pioneered the development of fractional laser resurfacing that relies on novel high-speed scanning systems and the Intelligent Optical Tracking® system to produce safe and effective results with minimal recovery time. Reliant is based in Mountain View, Calif. For more information, visit www.fraxel.com.
Reliant Technologies, Inc.
Download Press Release ••